Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Added: 2 months ago Source:  Radcliffe Cardiology
An artificial intelligence (AI) algorithm can identify high-risk coronary plaques on optical coherence tomography (OCT) images and predict adverse outcomes, according to findings from the PECTUS-AI study.¹ The research suggests that AI-assisted analysis of the entire imaged vessel provides superior prognostic value compared to manual analysis of a target lesion alone.Coronary thin-cap… View more
Author(s): Denisa Muraru Added: 1 month ago
Discover why tricuspid regurgitation aetiology matters for patient outcomes and intervention strategies with Prof Denisa MuraruThis presentation, part of a comprehensive series on complex cases in interventional cardiology, explores how understanding TR mechanisms directly impacts diagnosis, treatment selection, and clinical prognosis.Prof Muraru addresses the critical heterogeneity in TR… View more
Author(s): Santiago Garcia Added: 7 months ago
New York Valves 2025 - Early outcomes from an observational study with the PASCAL System show a 97% device success rate.Dr Santiago Garcia (The Christ Hospital, Cincinnati, OH, US) joins us to discuss a novel TEER device system. This observational study investigated the use of the PASCAL Prescision system in over 2000 patients from the STS/ACC/TVT registry over a period of two years.Findings… View more
Author(s): Thomas Modine Added: 8 months ago
EuroPCR25 - Findings from TRINITY trial show favourable outcomes with the LuX-Valve Plus TTVR system in high-risk patients with severe tricuspid regurgitation.We are joined by Prof Thomas Modine (CHU de Bordeaux, Bordeaux, FR) to discuss key findings from the TRINITY trial. This prospective, single-arm, multi-center study evaluated the LuX-Valve Plus transjugular tricuspid valve replacement… View more
Author(s): David Erlinge Added: 1 year ago
One-year outcomes from INFINITY-SWEDEHEART RCT recently presented at ESC 2024 demonstrated that DynamX Bioadaptor meets primary endpoint and significantly reduces adverse events compared to DES after six months. Dr David Erlinge, the primary investigator of INFINITY-SWEDEHEART RCT, shares a quick summary of the one-year outcomes presented at ESC 2024. He highlights how the novel design and… View more
Author(s): Vlasis Ninios Added: 2 months ago
PCR London Valves 2025 - Dr Vlasis Ninios (Interbalkan European Medical Center, GR) discusses one-year outcomes from the AltaValve Early Feasibility Study, evaluating a novel atrial fixation system for transcatheter mitral valve replacement in patients with severe mitral regurgitation.This prospective, single-arm, multicenter study enrolled high surgical risk patients with moderate to severe or… View more